(0 items)
Small Medium Large | Print-Friendly Version of this Page  | Email this Page to a Friend
Skip Navigation Links
Press Releases
Hot Topics
Statements
Comments
Correspondence
White Papers
Contact Public Relations
AABB > Press Room > Statements

Statements 

This section contains statements that have been released by AABB, its task forces or the entire blood community on issues relating to transfusion medicine and cellular therapies. Click on a link below to read current statements. For access to past statements, check our archive.

Joint Statement Before BPAC on The Immucor PreciseType™ HEA Molecular BeadChip, and Similar Assays - 3/18/14
Statement Before CTGTAC on “Draft Guidance for Industry: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products” - 2/26/14
Joint Statement Before BPAC on HTLV Confirmatory Test Developed by MP Biomedicals: MP Diagnostics HTLV Blot 2.4 - 11/1/13
Joint Statement Regarding "National Gay Blood Drive" - 6/26/13
Joint Statement Before BPAC on Labeling of Red Blood Cell Units with Historical Antigen Typing Results - 12/4/12
Statement Before BPAC on Considerations for Options to Further Reduce the Risk of Bacterial Contamination in Platelets - 9/21/12
Statement on AABB Tissue Biovigilance Initiative - 8/21/12
Statement on AABB’s National Blood Exchange - 8/8/12
Statement to the Radiological Devices Panel of the Medical Devices Advisory Committee - 4/12/12
AABB Statement on XMRV – 9/22/11
Joint Statement Before BPAC on Maintaining a Safe and Adequate Supply of Donated Blood During a Severe Emergency – 8/3/11
Joint Statement Before BPAC on T. cruzi Incidence Study of Blood Donors and Its Implications for Selective Donor Testing – 8/2/11
Statement Before ACBSA on Patient Blood Management – 6/8/11
Statement Before BPAC on the Donor Written Statement of Understanding – 4/29/11
Statement Before BPAC by Interorganizational Plasma Task Force on Plasma for Further Manufacture – 4/28/11
AABB Statement on XMRV – 2/10/11
Statement Before BPAC on Murine Leukemia Virus (MLV) Related Retroviruses and Blood Safety - 12/14/10
Joint Statement Before BPAC on Risk of Dengue Virus Infection in Blood Donors - 12/14/10
Statement Before BPAC on Hemoglobin/Hematocrit Acceptance Standards and Interdonation Intervals – 7/27/10
Statement Before BPAC on Babesia Infection Risk by Blood Transfusion and Potential Strategies for Donor Testing – 7/26/10
Joint Statement Before ACBSA on Donor Deferral for Men Who Have Had Sex with Another Man (MSM) – 6/15/10
Statement Before BPAC on Blood Pressure and Pulse as Blood Donor Eligibility Criteria – 11/17/09 (PDF)
Statement Before BPAC on Blood Donor Deferral for Malaria Risk Associated With Travel to Mexico – 11/16/09 (PDF)
Statement Before ACBSA on Decision Making Process for Transfusion and Transplantation Safety Policies – 5/1/09
Statement Before ACBSA on U.S. Biovigilance: Efforts to Bridge a Critical Donor and Patient Safety Gap – 4/30/09
Joint Statement Before BPAC on HBV NAT Using Triplex Assay Systems – 4/1/09
Joint Statement Before BPAC on Potential Testing Strategies for T. cruzi Infection in Blood Donors – 4/1/09
Presentation Before BPAC by the AABB Interorganizational Plasma Task Force – 4/2/09 (PDF)

 
Home  |  Site Map  | AABB © 2014. All rights reserved. |  Privacy Statement  |  Terms of Use